On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.
Neurogenetics

Charcot-Marie-Tooth 1A

CMT1A is a progressive disorder impacting nerves in the arms and legs, causing muscle weakness, numbness, and difficulties with movement. It typically manifests in childhood or adolescence and affects approximately 1 in 2,500 people in the UK.

Autosomal dominant Neurogenetics Tier A OMIM:118220
1:2,500
Prevalence
Population estimate
50%
Inheritance
Autosomal dominant - each child of a parent who has the variant has a 50% chance of inheriting it
1
Associated genes
PMP22

Overview

Charcot-Marie-Tooth disease is a group of inherited conditions that affect the peripheral nervous system. These nerves transmit signals between the brain and spinal cord and the rest of the body. CMT1A is the most common subtype of Charcot-Marie-Tooth disease. It is characterised by damage to the myelin sheath, which is the protective covering around nerve fibres [PMID:33678438]. This damage slows down nerve conduction, impairing the ability of nerves to send messages effectively to muscles and from sensory receptors.

CMT1A typically presents with slowly progressive muscle weakness and wasting, particularly in the lower legs and feet, and later in the hands and forearms. Affected individuals may also experience sensory loss, leading to numbness, tingling, or reduced sensation. The severity of symptoms can vary considerably, even within the same family, but CMT1A is generally considered a slowly progressive condition.

Symptoms & clinical features

The symptoms of CMT1A often begin in childhood or adolescence, although the exact age of onset can vary. Initial signs frequently include weakness in the muscles below the knees, leading to difficulties with walking and foot deformities. A common early symptom is 'foot drop', where the foot struggles to lift at the ankle, causing a high-stepping gait to avoid tripping [PMID:24610196].

Over time, muscle wasting (atrophy) can become noticeable in the lower legs, giving them a characteristic 'inverted champagne bottle' appearance. Deformities such as high arches (pes cavus) and hammer toes are also common. As the condition progresses, similar weakness and wasting may affect the hands and forearms, leading to problems with fine motor skills, such as writing or fastening buttons. Sensory symptoms, including numbness, pins and needles, or reduced sensation to touch, pain, and temperature, typically occur in the hands and feet.

Video: Genetics 101

Affected organs

CMT1A primarily affects the peripheral nerves, which are the nerves outside the brain and spinal cord. These nerves are responsible for transmitting signals to and from muscles (motor nerves) and carrying sensory information back to the brain (sensory nerves). The damage in CMT1A specifically impacts the myelin sheath of these nerves. The myelin sheath is a fatty layer that insulates nerve fibres, allowing electrical impulses to travel quickly and efficiently.

Because the peripheral nerves extend throughout the limbs, the primary organs affected are the muscles of the lower legs, feet, hands, and forearms. Sensory receptors in the skin of the extremities are also impacted. While the central nervous system (brain and spinal cord) is generally not directly affected by CMT1A, the impaired nerve signalling has widespread consequences for motor function and sensation in the limbs.

Brain
Brain
Central nervous system involvement
Nervous system
Nervous system
Peripheral nerve involvement

Risks & severity

CMT1A is a progressive condition, meaning symptoms tend to worsen gradually over time. However, the rate of progression and overall severity can vary significantly among individuals. Some people may experience mild symptoms that have little impact on daily life, while others may face more significant challenges with mobility and dexterity [PMID:33678438]. The condition does not typically affect life expectancy.

Complications can include chronic pain due to nerve damage, muscle cramps, and difficulties with balance, increasing the risk of falls. In some cases, respiratory muscle weakness can occur, though this is rare and usually only seen in severe, advanced stages. The development of foot ulcers due to sensory loss is also a potential risk, highlighting the importance of regular foot care. Onset is usually in childhood or adolescence, but subtle signs might be present earlier or later.

Genetic causes

Charcot-Marie-Tooth type 1A is caused by a duplication of a specific region on chromosome 17, which includes the PMP22 gene. This means that individuals with CMT1A have three copies of the PMP22 gene instead of the usual two [PMID:24610196]. The PMP22 gene provides instructions for making a protein called peripheral myelin protein 22, which is a critical component of the myelin sheath.

When there are too many copies of the PMP22 gene, an excess of the PMP22 protein is produced. This overproduction disrupts the normal structure and function of the myelin sheath around peripheral nerves. This abnormal myelin is unstable and tends to break down, leading to demyelination (loss of myelin) and remyelination (repair attempts), which results in abnormally slow nerve conduction and impaired nerve function. This ultimately causes the muscle weakness and sensory problems characteristic of CMT1A.

  • PMP22
    peripheral myelin protein 22

Inheritance pattern

CMT1A has an autosomal dominant pattern of inheritance. This means that a person only needs to inherit one copy of the altered PMP22 gene (the duplicated region on chromosome 17) from one parent to develop the condition. If a parent has CMT1A, there is a 50% chance with each pregnancy that their child will inherit the condition, regardless of the child's sex.

CMT1A can also occur in individuals with no family history of the condition due to a new, spontaneous gene duplication. In such cases, the affected individual would then have a 50% chance of passing the condition on to their own children. Genetic counselling can provide detailed information about inheritance patterns and risks for family members.

♀ Affected parent 1 altered copy ♂ Unaffected parent 2 typical copies Affected Unaffected Unaffected Affected Affected Carrier Unaffected Circles = females · Squares = males

Each child of an affected parent has a 50% chance of inheriting the pathogenic variant, regardless of sex.

Diagnosis & testing

Diagnosis of CMT1A typically begins with a detailed clinical assessment, including a neurological examination to evaluate muscle strength, sensation, and reflexes. Nerve conduction studies (NCS) and electromyography (EMG) are often used to measure how quickly electrical signals travel through nerves and to assess muscle electrical activity. These tests commonly show significantly slowed nerve conduction velocities, especially in motor nerves, which is characteristic of demyelinating neuropathies like CMT1A.

Confirmation of CMT1A is achieved through genetic testing, which looks for the specific duplication of the PMP22 gene. This can be done via microarray analysis or other molecular genetic techniques. In the UK, genetic testing for CMT1A is available through the NHS Genomic Medicine Service (GMS) pathways. Referrals for genetic testing typically come from a neurologist or a clinical geneticist. The relevant R-code for hereditary motor and sensory neuropathy (HMSN), which includes CMT, is R140.

Management & lifestyle

Currently, there is no cure for CMT1A, but management focuses on alleviating symptoms, improving function, and maintaining quality of life. A multidisciplinary approach involving several healthcare professionals is often beneficial. This team may include neurologists, physiotherapists, occupational therapists, orthotists, and podiatrists.

Physiotherapy is crucial for maintaining muscle strength, flexibility, and balance, and for preventing contractures. Occupational therapy can help individuals adapt to daily tasks and suggest assistive devices for improved independence. Orthotic devices, such as ankle-foot orthoses (AFOs), are often prescribed to help with foot drop, support the foot, and improve walking stability. Regular podiatry care is important for managing foot deformities and preventing complications like calluses and ulcers. In some cases, orthopaedic surgery may be considered to correct severe foot deformities. Regular reviews with a neurologist or clinical geneticist are important to monitor progression and adjust management strategies as needed.

UK care pathway

In the UK, individuals suspected of having CMT1A would typically be referred to a neurologist for initial assessment and diagnosis. If an inherited condition is suspected, they would then be referred to a clinical genetics service. These services provide expert advice, diagnostic testing through the NHS Genomic Medicine Service, and genetic counselling. Genetic counselling offers support and information to individuals and families affected by genetic conditions, explaining inheritance patterns, recurrence risks, and available management options.

Genetic testing for CMT1A and other hereditary neuropathies is performed under specific R-codes within the NHS GMS, such as R140 for hereditary motor and sensory neuropathy. This ensures that testing is carried out in accredited laboratories and results are interpreted by specialists. Ongoing care and management are usually coordinated through local neurology services, with input from allied health professionals.

Frequently asked questions

Is Charcot-Marie-Tooth disease always inherited?

Most forms of Charcot-Marie-Tooth disease, including CMT1A, are inherited. However, a small number of cases can arise from new genetic changes that occur spontaneously in an individual, meaning there is no prior family history.

Will my children inherit CMT1A if I have it?

CMT1A is inherited in an autosomal dominant pattern. This means if you have CMT1A, there is a 50% chance with each pregnancy that your child will inherit the genetic change and develop the condition.

Are there different types of Charcot-Marie-Tooth disease?

Yes, there are many different types of Charcot-Marie-Tooth disease. They are classified based on the genetic cause, the pattern of nerve damage (demyelinating or axonal), and how they are inherited. CMT1A is the most common demyelinating form.

What kind of exercise is safe for someone with CMT1A?

Generally, low-impact exercises like swimming, cycling, and walking (with appropriate orthotics if needed) are beneficial for maintaining strength and flexibility. It is advisable to consult a physiotherapist experienced with CMT to develop a safe and effective exercise plan.

Can CMT1A affect parts of the body other than the limbs?

CMT1A primarily affects the peripheral nerves in the arms and legs, leading to problems in those limbs. In very rare and severe cases, some respiratory muscle weakness can occur, but this is uncommon and usually only seen in advanced stages.

References

  1. Msheik Z, Durand S, Pinault E. Charcot-Marie-Tooth-1A and sciatic nerve crush rat models: insights from proteomics. Neural regeneration research. 2023. PMID: 36453423
  2. McGrath MC. Charcot-Marie-Tooth 1A: A narrative review with clinical and anatomical perspectives. Clinical anatomy (New York, N.Y.). 2016. PMID: 26457477
  3. Zlotogora J. Dominance and homozygosity. American journal of medical genetics. 1997. PMID: 9021013
  4. Baets J, De Jonghe P, Timmerman V. Recent advances in Charcot-Marie-Tooth disease. Current opinion in neurology. 2014. PMID: 25110935
  5. Hanemann CO, Müller HW. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy. Trends in neurosciences. 1998. PMID: 9683317
  6. Tozza S, Aceto MG, Pisciotta C. Postural instability in Charcot-Marie-Tooth 1A disease. Gait & posture. 2016. PMID: 27491052
  7. Murray GC, Hines TJ, Tadenev ALD. Testing SIPA1L2 as a modifier of CMT1A using mouse models. bioRxiv : the preprint server for biology. 2023. PMID: 38076977
  8. Lencioni T, Rabuffetti M, Piscosquito G. Postural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjects. Gait & posture. 2014. PMID: 25082324
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor.